Czech University of Life Sciences, Prague, Czech Republic
Alderete, John F
Washington State University
USA
Dr. Alderete was Professor at the U. Texas Health Science Center at San Antonio for 30 years prior to becoming Professor at the School of Molecular Biosciences, WSU-Pullman. He is recognized nationally and internationally for his basic research delineating mechanisms of pathogenesis by studying the biology of T. vaginalis. He is the inventor of the OSOM™ POC diagnostic for women with this STI. He is dedicated to inventing an approach to develop infectious disease diagnostics and a new diagnostic for serologic surveillance for this STI for low-resource environments worldwide. He is founder of two companies to commercialize these POC diagnostics.
Chang Yi Wang
United Biomedical Asia (UBI Asia)
Taiwan
Chang Yi Wang is the Chairperson and CSO of United Biomedical Asia (UBI Asia), a member of the UBI group of companies she founded dedicated to the discovery, development, and commercialization of immunotherapies & vaccines for chronic and infectious diseases. She is passionate about delivering science-driven innovation with platform capabilities. She has had an astonishing career, from being the first Asian woman accepted into Rockefeller University’s Ph.D. program back in 1973, the Nobel Laureate professors or board members she was trained under and worked with, and leveraged her research and management experience at a young age to establish UBI, and her strategy behind keeping proprietary manufacturing technologies in house, among other key areas.
Sherif T. S. Hassan
Czech University of Life Sciences
Prague, Czech Republic
Dr. Hassan is a distinguished researcher renowned for his pioneering efforts in exploring the antiviral potential of natural products-derived chemicals, with a specific focus on combating human herpesviruses, including herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). Leveraging rigorous preclinical studies, Dr. Hassan and his dedicated team have identified promising compounds demonstrating robust antiviral efficacy against these pathogens. Building upon these significant findings, Dr. Hassan's research has seamlessly transitioned into clinical studies, representing a pivotal stride towards translating scientific discoveries into tangible therapeutic interventions.